GeneDx Holdings Corp. (WGS)
Technology · NasdaqGS · US
Fundamentals
Valuation and ratings
GeneDx Holdings Corp. trades at USD61.69. We do not hold enough of the inputs to run a discounted cash flow on this company, so we publish no fair value for it rather than a number we would not defend.
About GeneDx Holdings Corp.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
WGS passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Smart money ownership
15 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Keith Meister, Corvex Management LP$207.31M · 8.2% of book
- Cathie Wood, ARK Investment Management LLC$85.06M · 0.7% of book
- Ken Griffin, CITADEL ADVISORS LLC$41.58M · 0.0% of book
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$9.87M · 0.0% of book
- Capital Research Global, Capital Research Global Investors$9.70M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Which funds own WGS?
15 of the institutions we track reported a position in WGS in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
The full research page for WGS, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.